Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

hytocystatin CsinCPI-2 Reduces Osteoclastogenesis and Alveolar Bone Los

Full text
Author(s):
Show less -
Leguizamon, N. Da Ponte [1] ; de Molo, R. S. [1] ; Coletto-Nunes, G. [1] ; Nogueira, A. V. B. [2] ; Rocha, V, S. ; Neo-Justino, D. M. [3] ; Soares-Costa, A. [3] ; Cerri, P. S. [4] ; Lerner, U. H. [5] ; Souza, P. P. C. [6] ; Cirelli, J. A. [1]
Total Authors: 11
Affiliation:
[1] Sao Paulo State Univ UNESP, Sch Dent, Dept Diag & Surg, Rua Humaita 1680, BR-14801903 Araraquara, SP - Brazil
[2] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Periodontol & Operat Dent, Mainz - Germany
[3] Rocha, S., V, Univ Fed Sao Carlos, Dept Genet & Evolut, Sao Carlos - Brazil
[4] Sao Paulo State Univ UNESP, Dept Morphol Genet Orthodont & Pediat Dent, Araraquara, SP - Brazil
[5] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res, Dept Internal Med & Clin N, Gothenburg - Sweden
[6] Univ Fed Goias, Fac Dent, Innovat Biomat Lab, Av Univ Esq 1a Ave S-N, BR-74605220 Goiania, Go - Brazil
Total Affiliations: 6
Document type: Journal article
Source: JOURNAL OF DENTAL RESEARCH; v. 101, n. 2 JUL 2021.
Web of Science Citations: 1
Abstract

Periodontal disease (PD) is a polymicrobial chronic inflammatory condition of the supporting tissues around the teeth, leading to the destruction of surrounding connective tissue. During the progression of PD, osteoclasts play a crucial role in the resorption of alveolar bone that eventually leads to the loss of teeth if the PD is left untreated. Therefore, the development of antiresorptive therapies targeting bone-resorbing cells will significantly benefit the treatment of PD. Here, we demonstrate the inhibitory effect of CsinCPI-2, a novel cysteine peptidase inhibitor from the orange tree, on periodontitis-induced inflammation, alveolar bone loss, and osteoclast differentiation. Using the ligature-induced periodontitis model in mice, we show that treatment with CsinCPI-2 (0.8 mu g/g of body weight) significantly reduced inflammatory cell infiltrate in the connective tissue and prevented the loss of alveolar bone mass (BV/TV) caused by PD, effects associated with diminished numbers of TRAP-positive multinucleated cells. Furthermore, CsinCPI-2 significantly downregulated the numbers of inflammatory cells expressing CD3, CD45, MAC387, and IL-1 beta. In vitro, CsinCPI-2 inhibited RANKL-induced TRAP+ multinucleated osteoclast formation in mouse bone marrow macrophage cultures in a concentration-dependent manner. This effect was not due to cytotoxicity, as demonstrated by the MTT assay. CsinCPI-2 inhibited RANKL-induced mRNA expression of Acp5, Calcr, and Ctsk, as well as the RANKL-induced upregulation of Nfatc1, a crucial transcription factor for osteoclast differentiation. Based on our findings, CsinCPI-2 prevents bone loss induced by PD by controlling the inflammatory process and acting directly on osteoclastogenesis, suggesting an interesting potential for CsinCPI-2 in the strategy for PD treatment. (AU)

FAPESP's process: 14/05283-3 - The effect of bradykinin on osteoclastogenesis in vitro and LPS-induced bone resorption in vivo
Grantee:Pedro Paulo Chaves de Souza
Support Opportunities: Research Grants - Young Investigators Grants
FAPESP's process: 18/10727-9 - Phytocystatins Csin-CPI-2 as a possible therapeutic candidate for treatment of periodontal disease and rheumatoid arthritis
Grantee:Ewelin Gabrielle Cardoso Goes
Support Opportunities: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 18/10728-5 - A new therapeutic approach to inhibit bone loss using phytocystatin Csin-CPI-2 for the treatment of metabolic bone diseases
Grantee:Ana Carolina Cindio
Support Opportunities: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 16/09876-4 - Periodontitis and Rheumatoid Arthritis - Association, Dual Treatment and Resolution
Grantee:Rafael Scaf de Molon
Support Opportunities: Scholarships abroad - Research Internship - Post-doctor
FAPESP's process: 15/21697-5 - A potentially new class of bone-protective drugs, phytocystatin from sweet orange Csin-CPI-2, as possible therapeutic candidate for treatment of bone diseases.
Grantee:Rafael Scaf de Molon
Support Opportunities: Scholarships in Brazil - Post-Doctorate